Kerbside

MARGINS WITH MUSCLE  [EasyDNNnews:PaidContentStart]

Granules India
BSE Code: 532482
CMP: ₹621.15 

game. The pharma maker, with a strong foothold across APIs, PFIs and finished dosages, is now leaning into smarter growth. Its backward integration, with four of five key APIs made in house, keeps costs under control and margins steady. What is changing now is the product mix. Granules is pushing harder into limited-competition launches in therapies such as CNS, ADHD, oncology and diabetes, while steadily raising its R&D spend. That shift is helping cushion the pain from price erosion in older molecules and past remediation costs. The bigger story may be ahead. With remediation costs easing, complex formulations gaining share, and the Senn & Ascelis business expected to improve, Granules appears to be entering a firmer earnings phase. Peak capex seems largely done, and stronger free cash flow from FY27 could give the Street one more reason to stay interested. 

POWERPLAY PHARMA 

Laurus Labs
BSE Code: 540222
CMP: ₹991.85 

Laurus Labs has been one of the standout pharma performers in FY26, with the stock rising over 60 per cent during the year. After that strong run, the recent correction has brought it back on the radar. Street chatter suggests the Rs 950 zone is a key support, and the pullback is being seen by some as a second chance for those who missed the earlier move. The optimism is not just technical. Earnings expectations remain strong, which gives the stock a bit more backing than pure momentum plays. If support holds and numbers stay firm, Laurus could remain a powerplay name in the short to medium term. 

THE NEXT POWER BET 

ACME Solar Holdings
BSE Code: 544283
CMP: ₹261.50 

ACME Solar has moved well beyond plain solar projects and is now strengthening its presence in hybrid and round-the-clock renewable power. The company is among the larger independent renewable power producers in India, with a portfolio spanning solar, wind, hybrid and FDRE projects. What stands out is its early push into battery energy storage and dispatchable green power, where demand is likely to deepen as the grid seeks more reliable renewable supply. The company’s expansion also appears measured rather than reckless. Management has focused on project selection, return ratios and financial discipline instead of chasing capacity for the sake of it. With a target of 10 GW by FY30, manageable debt and increasing expo sure to future-ready solutions, ACME Solar looks well placed to benefit as India’s renewable story becomes more about quality and consistency than just capacity. 

SCALE MEETS MARGIN 

Entero Healthcare Solutions
BSE Code: 544122
CMP: ₹1,245.85 

Entero Healthcare is showing that growth and discipline can travel together. In Q3FY26, the company reported 25.6 per cent revenue growth, with organic growth at 14.2 per cent, while EBITDA margin improved to 4 per cent and operating cash flow turned positive at ₹49 crore. The bigger trigger, though, is the medtech push. Entero closed seven acquisitions year-to-date, including three in medtech, and expects medtech revenue to cross ₹1,000 crore in the next financial year